Chapel Hill, NC17 Active Studies

Pulmonary Hypertension Clinical Trials in Chapel Hill, NC

Find 17 actively recruiting pulmonary hypertension clinical trials in Chapel Hill, NC. Connect with local research sites and explore new treatment options.

17
Active Trials
15
Sponsors
10,548
Enrolling

Recruiting Pulmonary Hypertension Studies in Chapel Hill

About Pulmonary Hypertension Clinical Trials in Chapel Hill

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 17 pulmonary hypertension clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 10,548 participants. Research is being sponsored by Population Health Research Institute, Case Western Reserve University, Case Comprehensive Cancer Center and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Chapel Hill — FAQ

Are there pulmonary hypertension clinical trials in Chapel Hill?

Yes, there are 17 pulmonary hypertension clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chapel Hill?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.

Are clinical trials in Chapel Hill free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 17 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated September 2, 2026 from ClinicalTrials.gov